A Phase 1/2, Open-label, Dose-Escalation Multi-center Study to Assess the Safety, Tolerability, PK and PD of Orally Administered NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF.
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 03 Apr 2018
At a glance
- Drugs NS 018 (Primary)
- Indications Myelofibrosis; Polycythaemia vera; Thrombocytosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors NS Pharma
- 27 Mar 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Oct 2019.
- 26 Sep 2017 Planned primary completion date changed from 1 Oct 2016 to 1 Dec 2017.
- 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History